Stoke Therapeutics, Inc. - Common Stock (STOK)
Frequently Asked Questions About Stoke Therapeutics, Inc. - Common Stock (STOK)
Has Stoke Therapeutics received any funding?
Yes, Stoke Therapeutics has successfully raised significant funding through various investment rounds since its inception. The company has attracted investments from prominent venture capital firms and institutional investors, which have supported the advancement of its research and development initiatives. Additionally, the proceeds from its initial public offering (IPO) were allocated towards the advancement of its clinical programs and expanding its research capabilities.
How does Stoke Therapeutics address patient engagement?
Stoke Therapeutics recognizes the importance of patient engagement and strives to incorporate patient perspectives into its research and development processes. The company actively communicates with patient advocacy groups and engages with individuals affected by the diseases it aims to treat. By understanding patient needs, Stoke can align its clinical trials, product development, and educational efforts to better serve the patient community and ensure that its therapies meet real-world needs.
How does Stoke Therapeutics view corporate social responsibility?
Stoke Therapeutics is committed to corporate social responsibility and aims to make a positive impact on the communities in which it operates. The company focuses on fostering an inclusive workplace, supporting diversity in the biotechnology field, and emphasizing ethical research practices. Stoke also engages in educational partnerships and initiatives designed to raise awareness about genetic disorders and promote patient access to treatments. By prioritizing its corporate responsibilities, Stoke seeks to contribute to broader societal goals while advancing its therapeutic mission.
Is Stoke Therapeutics a public company?
Yes, Stoke Therapeutics is a publicly traded company. It was listed on the Nasdaq stock exchange under the ticker symbol STOK. The company went public in 2020, allowing it to raise capital to support its research and development efforts as well as expand its pipeline of RNA-targeted therapies. Being publicly traded provides Stoke with greater visibility and access to funding for its innovative projects.
What are some of the company's lead product candidates?
Stoke Therapeutics is advancing several lead product candidates, with its most notable being STK-001, designed for the treatment of Dravet syndrome. STK-001 aims to increase the production of the SCN1A protein to restore normal neuronal function in affected individuals. Alongside STK-001, the company is developing additional candidates targeting other genetic disorders, showcasing its commitment to a diverse pipeline of potential therapies.
What are the company's clinical trials focused on?
Stoke Therapeutics' clinical trials are primarily focused on evaluating the safety and efficacy of its lead product candidates in treating conditions like Dravet syndrome and other related genetic disorders. The trials aim to assess the pharmacokinetics, dose response, and overall clinical outcomes in participants. By conducting rigorous clinical studies, Stoke seeks to generate robust data that supports regulatory approval and ultimately brings new treatments to market.
What are the company's financial highlights?
As a publicly traded entity, Stoke Therapeutics shares its financial performance through quarterly and annual reports. The company's financial highlights include revenue generated from potential future product sales and investments received from venture capital. While in the early stages of development, Stoke is focused on advancing its clinical programs, which may drive revenue and valuation in the future as its candidates move closer to commercialization.
What challenges does Stoke Therapeutics face?
Stoke Therapeutics, like many biotechnology companies, faces several challenges, including the inherent risks associated with drug development, competition from other therapies, and regulatory hurdles. Additionally, ensuring effective patient recruitment for clinical trials can be a challenge, especially in rare disease populations. The company must also navigate the dynamic landscape of biotechnology funding and market access as it strives to bring its innovative therapies to patients.
What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative RNA-targeted medicines specifically designed to treat genetically defined diseases. The company leverages its proprietary technology platform, known as the Targeted Augmentation of Nuclear Gene Expression (TANGO), to enhance the expression of proteins that are deficient or dysfunctional in diseases. Stoke aims to transform the treatment landscape for patients with severe genetic disorders, particularly those affecting the central nervous system.
What indications is Stoke Therapeutics targeting?
Stoke Therapeutics is primarily targeting severe genetic disorders, particularly those related to the central nervous system. One of its leading programs focuses on Dravet syndrome, a rare and severe form of epilepsy caused by mutations in the SCN1A gene. The company is also exploring additional indications, including other genetic epilepsies and neurodegenerative conditions, leveraging its TANGO technology to develop new therapeutic options.
What is TANGO technology?
TANGO technology, or Targeted Augmentation of Nuclear Gene Expression, is Stoke Therapeutics' proprietary platform designed to enhance gene expression through RNA modulation. This innovative approach allows the company to selectively increase the production of functional proteins that may be underexpressed due to genetic mutations. TANGO is a pioneering method in the field of RNA-targeted therapies, offering potential to address a wide range of genetically defined diseases.
What is the company's approach to drug development?
Stoke Therapeutics employs a rigorous scientific approach to drug development that combines cutting-edge research in RNA biology with a focus on addressing specific genetic disorders. The company utilizes its TANGO technology to develop drug candidates that aim to restore the normal function of genes affected by mutations. Stoke emphasizes collaboration with leading researchers and institutions, conducting preclinical and clinical studies to ensure the safety and efficacy of its therapies in patients.
What is the potential market for Stoke Therapeutics' products?
The market potential for Stoke Therapeutics' products is substantial, particularly in the realm of rare genetic disorders and neurological diseases such as epilepsy. Dravet syndrome, for instance, has no approved disease-modifying therapies, creating a significant unmet medical need. As the understanding of genetic diseases grows and RNA-focused therapies gain acceptance, Stoke's innovative approach could capture a significant share of the market for targeted therapeutics, enhancing the lives of patients.
What partnerships or collaborations does Stoke Therapeutics have?
Stoke Therapeutics has established partnerships and collaborations with various academic institutions and biopharmaceutical companies to enhance its research capabilities and accelerate its drug development efforts. Collaborations with leading scientific minds and organizations allow Stoke to leverage external expertise and resources. By fostering such strategic alliances, the company aims to advance its understanding of genetic diseases and support its pipeline of RNA-targeted therapies.
What regulatory status do Stoke's product candidates have?
Stoke Therapeutics is working within the regulatory framework established by the U.S. Food and Drug Administration (FDA) as it progresses its product candidates through clinical development. The company has submitted investigational new drug (IND) applications for its clinical programs, including STK-001 for Dravet syndrome. As clinical trials progress and data is collected, Stoke will continue to engage with regulatory authorities to seek approval for its therapies aimed at addressing serious medical conditions.
When was Stoke Therapeutics founded?
Stoke Therapeutics, Inc. was founded in 2018. The company emerged from research conducted at the University of Texas Southwestern Medical Center, where advancements in RNA biology and gene expression highlighted new therapeutic opportunities for genetic disorders. Since its inception, Stoke has focused on translating scientific discoveries into potential treatments that address unmet medical needs for patients.
Where is Stoke Therapeutics headquartered?
Stoke Therapeutics is headquartered in Bedford, Massachusetts. This location positions the company within a vibrant biotech ecosystem, allowing it to collaborate with leading scientific institutions, access talent, and engage with investors. The headquarters serves as the central hub for the company's research, development, and corporate operations.
Who are the founders of Stoke Therapeutics?
Stoke Therapeutics was co-founded by a team of accomplished scientists and entrepreneurs, including Dr. Aarti Khosla and Dr. Eric Olson. Dr. Olson is a renowned researcher in the field of muscle biology and gene therapy and has contributed significantly to the development of new drug candidates. Their leadership combines extensive expertise in genetics, molecular biology, and clinical development to drive the company’s mission forward.
Who are the key members of the management team?
Stoke Therapeutics' management team consists of experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and life sciences. Key members include Co-founder and CEO Dr. Aarti Khosla, who brings expertise in business strategy and drug development, and Chief Scientific Officer Dr. Eric Olson, known for his groundbreaking research in genetics. Together, they lead a dedicated team committed to advancing the company's mission to develop innovative therapies for patients with genetic disorders.
What is the current price of Stoke Therapeutics, Inc. - Common Stock?
The current price of Stoke Therapeutics, Inc. - Common Stock is 6.250
When was Stoke Therapeutics, Inc. - Common Stock last traded?
The last trade of Stoke Therapeutics, Inc. - Common Stock was at 3:12 pm EDT on April 3rd, 2025
What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 276.18M
How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
Stoke Therapeutics, Inc. - Common Stock has 44.19M shares outstanding.